Targinta has partnered with Abzena for initial production of its drug candidates. Abzena will perform initial chemistry manufacturing and control (CMC) activities and cell line development for both Targinta's ADC antibody TARG9 and for the function-blocking antibody TARG10.

“Abzena is delighted to collaborate with Targinta, a leading Nordic ADC company creating novel solutions for cancer patients. Our support includes ADC candidate design, and non-clinical and clinical manufacturing of bioconjugates and antibodies. I am very excited to see Targinta progress towards clinical development in partnership with Abzena”, commented Jonathan Goldman, CEO at Abzena.

"Abzena is a leading player in the ADC arena and the newly signed CMC collaboration represents an expansion of a long standing and very positive research collaboration between our companies. Abzena has been instrumental for the generation of Targinta's drug development candidates TARG9 and TARG10 and we have particularly appreciated Abzena's exceptional speed and attentiveness to our needs," says Per Norlén, CEO of Targinta.

Targinta develops tumor-targeting antibodies and ADCs against its unique and patent-protected target integrin α10β1 that is overexpressed in certain aggressive cancers. The start of production of the drug candidates is an important milestone for the company and provides potential to start clinical trials in cancer patients in the second half of 2024.

For further information please contact:
Per Norlén, CEO Targinta AB
E-mail: per.norlen@targinta.se
Phone: +46 46 275 65 00

About Abzena Ltd.
Abzena provides the most complete set of solutions in integrated early discovery to mid-phase biotherapeutic and bioconjugation drug development and manufacturing in the biopharmaceutical industry. The company maintains resources around the world, with facilities in the US and UK. Abzena is owned by Welsh, Carson, Anderson & Stowe, one of the world’s leading private equity investors. For more information, please see www.abzena.com

About Targinta AB
Targinta is a preclinical oncology company developing tumor-targeting antibodies and ADCs based on the in-house discovery of the unique target integrin α10β1 that is overexpressed in aggressive cancers like triple-negative breast cancer and glioblastoma. The pipeline consists of TARG10, a function-blocking integrin α10-antibody that counteracts metastasis, and TARG9, a toxin-conjugated integrin α10-antibody (ADC) that acts by direct killing of tumor cells. Targinta is a wholly owned subsidiary of Xintela AB (publ) headquartered in Lund, Sweden. For further information please refer to www.targinta.se.

About Xintela AB
Xintela develops medical products in stem cell therapy and targeted cancer therapy based on the Company's cell surface marker integrin α10β1 which is found on mesenchymal stem cells and on certain aggressive cancer cells. The stem cell marker is used to select and quality-assure the patent-protected stem cell product XSTEM®, which is in clinical development for treatment of knee osteoarthritis and difficult-to-heal leg ulcers. The company produces XSTEM for the clinical studies in its GMP-approved manufacturing facility. In cancer therapy, which is run by the wholly owned subsidiary Targinta AB, therapeutic antibodies, targeting integrin α10β1 (First-in-Class) are being developed for the treatment of triple-negative breast cancer and the brain tumor glioblastoma. Xintela conducts its business at Medicon Village in Lund, Sweden, and is listed on Nasdaq First North Growth Market Stockholm since 22 March 2016. Xintela's Certified Adviser at Nasdaq First North Growth Market is Erik Penser Bank AB, +46 8-463 80 00, certifiedadviser@penser.se.